American Century Companies Inc. Grows Stock Position in Celldex Therapeutics, Inc. $CLDX

Key Points

• American Century Companies Inc. has increased its stake in Celldex Therapeutics by 2.8%, holding 625,321 shares valued at approximately $11.35 million.
• Shares of Celldex Therapeutics have seen a 2.4% decline, with a current market cap of $1.46 billion and a twelve-month trading range of $14.40 to $47.00.
• Several analysts have revised their price targets for Celldex Therapeutics, with an average target of $46.67 and a consensus rating of "Moderate Buy."

American Century Companies Inc. raised its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 2.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 625,321 shares of the biopharmaceutical company's stock after purchasing an additional 16,864 shares during the quarter. American Century Companies Inc. owned 0.94% of Celldex Therapeutics worth $11,350,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Invesco Ltd. boosted its holdings in shares of Celldex Therapeutics by 2.1% in the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock valued at $1,064,000 after purchasing an additional 871 shares in the last quarter. Tudor Investment Corp ET AL acquired a new position in Celldex Therapeutics during the 4th quarter worth approximately $822,000. Deutsche Bank AG increased its holdings in shares of Celldex Therapeutics by 13.8% during the first quarter. Deutsche Bank AG now owns 138,289 shares of the biopharmaceutical company's stock worth $2,510,000 after buying an additional 16,788 shares in the last quarter. Deep Track Capital LP acquired a new position in shares of Celldex Therapeutics during the fourth quarter worth $38,919,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Celldex Therapeutics by 23.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock worth $89,890,000 after buying an additional 676,771 shares in the last quarter.

Celldex Therapeutics Stock Down 1.3%

NASDAQ CLDX traded down $0.30 on Friday, reaching $22.08. The company had a trading volume of 1,329,314 shares, compared to its average volume of 1,503,039. The stock has a market capitalization of $1.47 billion, a P/E ratio of -7.34 and a beta of 1.19. The company's fifty day moving average is $22.29 and its 200 day moving average is $20.62. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.01. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%.The business had revenue of $0.73 million during the quarter, compared to analyst estimates of $1.13 million. On average, research analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. UBS Group lowered their price target on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. Citigroup decreased their price objective on shares of Celldex Therapeutics from $56.00 to $48.00 and set a "buy" rating for the company in a research report on Wednesday, August 20th. Wells Fargo & Company decreased their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set an "overweight" rating for the company in a research report on Wednesday, August 20th. Morgan Stanley dropped their target price on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Finally, HC Wainwright dropped their target price on shares of Celldex Therapeutics from $50.00 to $42.00 and set a "buy" rating on the stock in a research report on Wednesday, August 20th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $46.67.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.